Everything you need to win Kent Hawryluk — in one platform.
Who to reach, what to say, and why now on Kent Hawryluk — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Kent Hawryluk — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
MBX Biosciences, Inc. announced the appointment of Salomon (Sam) Azoulay, M.D, as Chief Medical Officer (CMO).
Company Information
Company
MBX Biosciences, Inc.
Location
11711 N. Meridian Street, Suite 300
Carmel, Indiana, United States
About
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. The company is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX’s pipeline includes its lead product candidate MBX 2109, in Phase 2 development for the treatment of hypoparathyroidism (HP), MBX 1416, in Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH) and multiple discovery and pre-clinical candidates in development for the treatment of obesity.
CarmelBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma